{"id":223736,"date":"2025-10-21T04:30:35","date_gmt":"2025-10-21T09:30:35","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/10\/advancing-human-leukocyte-antigen-based-cancer-immunotherapy-from-personalized-to-broad-spectrum-strategies-for-genetically-heterogeneous-populations"},"modified":"2025-10-21T04:30:35","modified_gmt":"2025-10-21T09:30:35","slug":"advancing-human-leukocyte-antigen-based-cancer-immunotherapy-from-personalized-to-broad-spectrum-strategies-for-genetically-heterogeneous-populations","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/10\/advancing-human-leukocyte-antigen-based-cancer-immunotherapy-from-personalized-to-broad-spectrum-strategies-for-genetically-heterogeneous-populations","title":{"rendered":"Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/advancing-human-leukocyte-antigen-based-cancer-immunotherapy-from-personalized-to-broad-spectrum-strategies-for-genetically-heterogeneous-populations2.jpg\"><\/a><\/p>\n<p>Human leukocyte antigen (HLA)-based immunotherapeutics, such as tebentafusp-tebn and afamitresgene autoleucel, have expanded the treatment options for HLA-A*02-positive patients with rare solid tumors such as uveal melanoma, synovial sarcoma, and myxoid liposarcoma. Unfortunately, many patients of European, Latino\/Hispanic, African, Asian, and Native American ancestry who carry non-HLA-A*02 alleles remain largely ineligible for most current HLA-based immunotherapies. This comprehensive review introduces HLA allotype-driven cancer health disparities (HACHD) as an emerging research focus, and examines how past and current HLA-targeted immunotherapeutic strategies may have inadvertently contributed to cancer health disparities. We discuss several preclinical and clinical strategies, including the incorporation of artificial intelligence (AI), to address HACHD.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Human leukocyte antigen (HLA)-based immunotherapeutics, such as tebentafusp-tebn and afamitresgene autoleucel, have expanded the treatment options for HLA-A*02-positive patients with rare solid tumors such as uveal melanoma, synovial sarcoma, and myxoid liposarcoma. Unfortunately, many patients of European, Latino\/Hispanic, African, Asian, and Native American ancestry who carry non-HLA-A*02 alleles remain largely ineligible for most current HLA-based [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412,1495,6],"tags":[],"class_list":["post-223736","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics","category-health","category-robotics-ai"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/223736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=223736"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/223736\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=223736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=223736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=223736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}